Evidence map›Paper›PMID 31981860›Full record

ArticleMolecular therapy. Nucleic acids2020

Overexpressed lncRNA GATA6-AS1 Inhibits LNM and EMT via FZD4 through the Wnt/β-Catenin Signaling Pathway in GC.

Zheng-Tian Li, Xu Zhang, Da-Wei Wang, Jun Xu, Ke-Jian Kou, Zhi-Wei Wang, Gong Yong, De-Sen Liang, Xue-Ying Sun

RetractedAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Knockdown of long non-coding RNA RP11-297P16.3 inhibits the migration and invasion of laryngeal squamous carcinoma cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Zheng-Tian LiDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China.
Xu ZhangThe Hepatosplenic Surgery Center, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China; Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China.
Da-Wei WangDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China.
Jun XuDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China.
Ke-Jian KouDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China.
Zhi-Wei WangDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China.
Gong YongDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China.
De-Sen LiangDepartment of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China. Electronic address: ldsliangdesen@163.com.
Xue-Ying SunThe Hepatosplenic Surgery Center, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, P.R. China; Department of Molecular Medicine & Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand. Electronic address: sunxueyingdr@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Accumulating evidence reveals the significance of long non-coding RNAs (lncRNAs) in various cancers. The current study aimed to evaluate the role of GATA6 antisense RNA 1 (GATA6-AS1) in the epithelial-mesenchymal transition (EMT) and lymph node metastasis (LNM) in GC. GC-related microarray datasets were initially retrieved from the GEO with differentially expressed lncRNAs screened, followed by evaluation of the regulatory relationship between Frizzled 4 (FZD4) and GATA6-AS1. The detailed regulatory mechanism by which GATA6-AS1 influences the Wnt/β-catenin signaling pathway and GC cell biological behaviors was investigated by treating SGC7901 cells with overexpressed GATA6-AS1, specific antisense oligonucleotide against GATA6-AS1, and lithium chloride (LiCl; activator of the Wnt/β-catenin signaling pathway). Finally, xenograft nude mice were used to assay tumor growth and LNM in vivo. GATA6-AS1 was poorly expressed, but FZD4 was highly expressed in GC tissues and cells. Elevated GATA6-AS1 reduced FZD4 expression by recruiting enhancer of zeste homolog 2 (EZH2) and trimethylation at lysine 27 of histone H3 (H3K27me3) to the FZD4 promoter region via the inactivated Wnt/β-catenin signaling pathway, whereby cell invasion, migration, and proliferation, tumor growth, and LNM in nude mice were reduced. Taken together, overexpressed GATA6-AS1 downregulated the expression of FZD4 to inactivate the Wnt/β-catenin signaling pathway, which ultimately inhibited GC progression.

Indexed as

epithelial-mesenchymal transitionFZD4gastric cancerGATA6-AS1long non-coding RNAlymph node metastasisWnt/β-catenin signaling pathway

Identifiers

PMID31981860
PMCPMC6976905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.